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ABSTRACT Bullous Diseases Unit at the 2nd Department of Dermatology 
and Venereology, Aristotle University of thessaloniki was founded with 
the aim to provide the optimal diagnostic approach and treatment of pa-
tients with autoimmune bullous diseases (AΙBD).  We processed all AiBD 
files of patients diagnosed from 2011 to 2014 in order to record all epi-
demiological data and therapeutic manipulations during monitoring. 57 
patients were diagnosed with intraepidermal and 62 with subepidermal 
bullous diseases. there were 51 cases (89%) of pemphigus vulgaris (PV) 
and 6 (11%) of pemphigus foliaceus (PF), whereas 45 (73%) patients were 
diagnosed with bullous pemphigoid (BP), 9 (14%) with mucous membrane 
pemphigoid (MMP), 3 (5%) with pemphigoid gestationis (PG), 3 (5%) with 
linear igA dermatosis (lAD), 1 (2%) with epidermolysis bullosa aquisita 
(eBA), and 1 patient with an undefined subepidermal AiBD. the mean age 
of patients within the pemphigus spectrum was 57 years. in the pemphi-
goid spectrum, the mean age was 72 years. Comorbidities were reported 
with increasing frequency, as well as treatment options other than systemic 
corticosteroids, such as adjuvant immunosuppressive agents, which were 
used to achieve complete remission. 
this is a report from a tertiary AiBD referral Center in northern Greece. Our 
data from a 4-year period contribute to the completion of the global geo-
graphic incidence map of AiBD.
KEY WORDS: autoimmune bullous diseases, pemphigus, bullous pemphi-
goid
INTRODUCTION
Bullous dermatoses include a series of poten-
tially life-threatening autoimmune clinical entities 
characterized by bullae and erosions of the mucous 
membranes and skin (1). they are classified into 
two groups based on the level of formation of bul-
lae: the intraepidermal and subepidermal bullous 
diseases. 
intraepidermal bullous diseases are caused by the 
production of autoantibodies against components 
of the desmosomes. Destruction of the intercellu-
lar bridges causes detachment and separation of 
keratinocytes in the spinous layer of the epidermis, 
leading to the formation of intraepidermal blisters, 
which easily rupture and result in painful erosions 
(2). Subepidermal bullous diseases are caused by the 
production of autoantibodies against components of 
the dermoepidermal junction, ultimately resulting in 
the formation of subepidermal blisters (3).
the diagnostic approach that confirms the clini-
cal suspicion and determines each clinical subtype 
includes: a) histopathological analysis of a fresh (<24 
h) vesicle or 1/3 of the peripheral portion of a blis-
ter and 2/3 perilesional skin; b) direct immunofluo-
rescence microscopy (DiF) of perilesional skin (up 
to 1 cm from a fresh lesion, even though the skin is 
seemingly healthy); c) indirect immunofluorescence 
microscopy (iiF); d) serological detection of specific 
serum autoantibodies (Dsg1, Dsg3, BP180, BP230) by 
commercially available enzyme-linked immunosor-
bent assay (eliSA) kits; and e) immunoblotting that 
specifies the identity and molecular weight of target 
antigens (4-6). Confirmation of diagnosis is an impor-
tant determinant of any therapeutic decision. 
Systemic corticosteroids are considered the 
first-line therapy in the majority of cases in order to 
achieve clinical disease control and are maintained 
through the consolidation phase in decreasing dos-
es, to maintain remission. in case of refractory disease 
or contraindications to corticosteroids, immunosup-
pressive adjuvants are administered (azathioprine, 
mycophenolate mofetil, cyclophosphamide, myco-
phenolic acid, dapsone, methotrexate, sulfonamides, 
tetracycline, anti-CD20 or anti-ige monoclonal an-
tibody, intravenous immunoglobulins, immunoad-
sorption, and plasma exchange) (7,8).
the Bullous Diseases Unit at the 2nd Department 
of Dermatology and Venereology of the Aristotle 
University of thessaloniki operates at Papageorgiou 
General Hospital as a center for diagnosis, treatment, 
and monitoring of patients with autoimmune bul-
lous diseases from northern Greece. it conducts a 
comprehensive diagnostic approach to patients in 
collaboration with the laboratories of immunology 
and Molecular Biology, which lays the foundation for 
further individualized therapeutic management of 
this spectrum of diseases. in the context of long-term 
monitoring of patients, all therapeutic manipulations 
aim to achieve complete disease remission and good 
general health. the purpose of this study was to re-
cord epidemiological data, medical history, labora-
tory profiles, and therapeutic manipulations during 
monitoring.
PATIENTS AND METHODS
For this retrospective study, we studied the files of 
119 patients (n=119), who presented at our Bullous 
Diseases Unit in Papageorgiou General Hospital be-
tween January 2011 and December 2014. Diagnosis 
was confirmed by laboratory tests, and all patients 
met 2 necessary input criteria:
o Histopathology
o immunoassay (direct immunofluorescence mi-
croscopy) documenting the diagnosis “intraepider-
mal or subepidermal bullous disease”.
A complete immunoassay approach (indirect im-
munofluorescence microscopy, eliSA) was performed 
in all patients but remained an optional input criteri-
on, whereas immunoblotting was a selective method 
with ancillary contribution to the diagnosis. All pa-
tient sera were screened for the presence of specific 
igG autoantibodies (Dsg1, Dsg3, BP180, BP230) using 
commercially available eliSA kits according to the 
manufacturer’s instructions (euroimmun AG, lübeck, 
Germany).
We studied patient files retrospectively and re-
corded the following data: sex, ethnicity, date of birth, 
place of residence, date and patient age at the time of 
diagnosis of any bullous disease, clinical subtype of 
the disease, histopathology reports, titer of disease-
specific serum autoantibodies, therapeutic agents 
(drug, dosage, route of administration, date of treat-
ment initiation, treatment duration, date of treatment 
discontinuation, side-effects), patient compliance, 
eruption of new lesions throughout monitoring and 
relapses (number, date of recurrence, months from 
diagnosis, dosage at recurrence, corticosteroid dose 
to achieve disease control).
RESULTS
Over the study period, of the total 119 patients, 
57 (48%) were diagnosed with intraepidermal and 62 
(52%) with subepidermal bullous disease. All types 
of AiBD were observed: there were 51 cases (89%) of 
pemphigus vulgaris (PV) and 6 (11%) of pemphigus 
foliaceus (PF), whereas 45 (73%) patients were diag-
nosed with bullous pemphigoid (BP), 9 (14%) with 
mucous membrane pemphigoid (MMP), 3 (5%) with 
pemphigoid gestationis (PG), 3 (5%) with linear igA 
dermatosis (lAD), 1 (2%) with epidermolysis bullosa 
acquisita (eBA), and 1 patient with an undefined sub-
epidermal AiBD. no case of igA-pemphigus (iGAP) or 
paraneoplastic pemphigus (PnP) was found. table 1 
shows frequencies of the spectrum of intraepidermal 
and subepidermal bullous diseases, sex ratio, mean 
age, and age range. there were 32 men and 25 wom-
en in the pemphigus group with a male to female 
ratio of 1.27:1; ages ranged from 29 to 84 years, and 
mean age was 57 years. the pemphigoid group con-
sisted of 28 men and 34 women, the male to female 
ratio was 1:1.2, while the mean age was 72 years and 
the range 4 to 90 years.
the study also recorded a number of comorbidi-
ties from patient personal medical histories. table 2 
depicts the comorbidities most commonly observed 
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in our patients. in patients from the pemphigus 
group, there was an increased incidence of diseases 
associated with metabolic syndrome (hypertension, 
coronary disease – acute myocardial infarction – an-
gioplasty, dyslipidemia, diabetes mellitus) and osteo-
porosis. According to the literature, comorbidities in 
patients with intraepidermal bullous dermatoses are 
mainly attributed to the simultaneous presence of a 
second autoimmune disorder. in particular, associa-
tions with myasthenia gravis, thymoma, systemic lu-
pus erythematosus, psoriasis etc. have been record-
ed, a fact that makes a close and regular monitoring 
of these patients essential (9). in our study, we also 
observed many comorbidities in the pemphigoid 
group, mainly attributed to the elevated mean age of 
patients. nearly half of patients (48%) suffered from 
three or more chronic diseases at the time of diag-
nosis. incidence of diabetes mellitus in our study was 
38.7%, while in similar studies the incidence did not 
exceed 20% of BP patients. A possible correlation with 
antidiabetic medications cannot be excluded, as it is 
considered to be a putative trigger (9). Additionally, 
although strong associations have been observed 
between specific neurological diseases and the later 
development of BP, in our study only 5 out of 45 pa-
tients diagnosed with BP suffered from dementia or 
Parkinson’s disease (10).
regarding treatment with systemic steroids, the 
initial dose was 1-1.5 mg/kg/day prednisone equiva-
lent for intraepidermal bullous diseases and 0.5-1 
mg/kg/day prednisone equivalent for subepidermal 
bullous diseases. Adjuvant therapy with immuno-
suppressive agents was used as a therapeutic option 
beyond systemic corticosteroids in our group of pa-
tients in order to achieve complete disease remission. 
in some cases (epidermolysis bullosa aquisita, linear 
igA dermatosis), dapsone was used as first-line treat-
ment.
Adjuvant treatment with immunosuppressive 
and immunomodulatory agents was used during the 
corticosteroid tapering period (corticosteroid sparing 
regimens), in order to limit side-effects and compli-
cations associated with long-term corticosteroid use 
(>4 months) and in some recalcitrant cases. table 3 
shows all adjuvant therapeutic options and the dura-
tion of administration.
relapse was defined as the appearance of 3 or 
more new lesions/month or a large lesion (>10 cm) 
that did not heal spontaneously within a week, or the 
extension of the existing lesions in a patient who has 
achieved control of the disease (11). Of all treated pa-
tients with intraepidermal bullous diseases, 40.0% of 
them presented with one relapse, 17.6% had a second 
relapse, and 7.0% a third and fourth relapse. A relapse 
of the disease was observed in 21.0% of patients with 
subepidermal bullous diseases, while 3.2% of them 
presented with a second relapse, and only 1 patient 
(1.6%) had a third relapse. Diagram 1 depicts the per-
centage of patients who experienced relapse of the 
disease. Among patients from the pemphigus group 
who had the first relapse (13 in 62 patients – 21.0%), 
nearly half of them, 6 patients, relapsed while being 
treated with 5 mg prednisone equivalent. Among the 
pemphigoid group, 11 patients relapsed while being 
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Table 1. Characteristics of 119 Greek patients with different AiBD
Clinical subtype of Autoimmune Bullous 
Disease





Pemphigus Vulgaris (PV) 51 89,4 1,21:1   56,7 30-84
Pemphigus Foliaceus (PF) 6 10,5 2:1 59,6 29-80
57 100,0 1,27:1 57,0 29-84
Subepidermal Bullous Disease
Bullous Pemphigoid (BP) 45 72,6       1:1 76,1 55-90
Mucous Membrane Pemphigoid  
(MMP)
9 14,5     1:1,3 66,7 48-83
linear igA Dermatosis (lAD) 3 4,8       1:2 51,0         4-77
Pemphigoid Gestationis (GP) 3 4,8 F 36,3 32-40
epidermolysis Bullosa Acquisita (eBA) 1 1,6 F 70,0 70
Unidentified subepidermal disease 1 1,6 F 60,0 60
62 100,0       1:1,2 72,0  4-90
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treated with 5 mg prednisone equivalent, of a total 
23 in 57 patients – 40% – who experienced a first re-
lapse.
DISCUSSION
epidemiological studies from different countries 
have outlined the main features of AiBD per country 
(12-26).
Subepidermal bullous diseases are the most com-
mon AiBD in Western europe (France, Germany, and 
Switzerland). in China, Malaysia, iran, Kuwait, and in 
Mediterranean countries, studies report a predomi-
nance of intraepidermal over subepidermal AiBD, 
particularly in iran with a ratio of 8:1.
the geographical distribution of pemphigus is un-
equal. it can be released or exacerbated by a plurality 
of potential risk factors (genetic, environmental, nutri-
tional, UV radiation, trauma, pharmaceuticals). Some 
ethnicities, such as Jewish and Japanese, show an 
increased incidence of pemphigus. Countries with in-
creased incidence are Greece (0.93/100 000/year), tu-
nisia (0.67/100 000/year), Bulgaria (0.47/100 000/year), 
italy (0.25/100 000/year), and turkey (0.24/100 000/
year). However, the limitations of these epidemiologi-
cal studies are: 1) data in most studies were recorded 
at least 15 to 20 years ago, 2) certain records relate to 
specific regions rather than the whole population of 
the country, and 3) the samples are small. 
Geographical distribution of BP varies as well. re-
cent studies have shown increased incidence in the 
United Kingdom (43/million/year), France (21.7/mil-
lion/year), Germany (13.4/million/year), and Switzer-
land (12.1/million/year) compared with older studies 
from Western europe (6-7/million/year). 
Table 3. Adjuvant therapeutic agents and du-
ration of treatment
the most common pemphigus subtype in most 
countries is pemphigus vulgaris (PV), mainly in europe 
and the USA. it is particularly dominant in iran (92% 
PV, 7% PF), Kuwait (80% PV, 18% PF), turkey (83% PV, 
8% PF), and Bulgaria (77% PV, 17% PF). PF is more fre-
quent in South Africa, tunisia with endemic PF (36%), 
Brazil (rural), and other latin American countries 
where the endemic form fogo selvagem dominates. 
PF is the most common form in Finland, while PV and 
PF are found with equal prevalence in Morocco.
Mean age of onset of PV in Kuwait is 36 years and 
is similar in india, slightly higher in iran (42 years), 
turkey, Saudi Arabia, Singapore, tunisia, and South 
Africa, and even higher (>50 years) in most european 
countries, Korea, and Japan. Pemphigoid diseases 
manifest over the age of 75 years in many developed 
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Table 2. Patients’ comorbidities 




















• Coronary disease – Acute Myocardial infarction – Angioplasty
• Atrial Fibrillation
• Benign Prostatic Hyperplasia
• Dementia – Parkinson’s disease
• Stroke



























































countries (France 83.00 years, Portugal 79.60 years, 
Germany 77.3 years, United Kingdom 77.00 years), 
while the patients are younger in developing coun-
tries (tunisia 67.20 years, Kuwait 65.00 years, iran 
59.40 years).
increased incidence of AiBD in women compared 
with men has been reported in most countries. in 
contrast, AiBD are more common in men in Germany 
and China. 
Our study is the first epidemiological imprinting 
of the spectrum of autoimmune bullous diseases in 
northern Greece. Previous published data for north-
ern Greece included only cases with PV (27).
Direct immunofluorescence remains the gold 
standard in the diagnostic approach for AiBDs. Serra-
tion pattern analysis, however, is a recently described 
technique of direct immunofluorescence microscopy 
which may be useful in the differential diagnosis of 
subepidermal AiBD. Serration pattern analysis was 
not performed in our laboratory during the time pe-
riod of this study, which may have consequently led to 
an underestimation of patients with eBA (28). today, 
with the addition of detection of specific circulating 
autoantibodies using eliSA techniques, diagnostic 
criteria are supplemented and serological monitor-
ing of pemphigus disease activity is possible. in one 
recent study of our group, it has been demonstrated 
that the titer of autoantibodies against Dsg1 corre-
lates strongly with the clinical status of skin lesions, 
whereas the titer of autoantibodies against Dsg3 
may still remain high after the recession of mucosal 
lesions (29). eliSA techniques that are now available 
also became part of the diagnostic evaluation of 
pemphigoid diseases. Circulating antibodies target 
two hemidesmosomal proteins. BP230 is an intracel-
lular glycoprotein, but circulating antibodies against 
this antigen do not correlate with disease activity. 
On the other hand, autoantibody levels against the 
nC16A domain of the BP180 antigen could be very 
helpful in monitoring disease activity and choosing 
the best therapeutic approach (30).
therapeutic strategy in most countries follows the 
basic principles of the AiBD guidelines, and the only 
deviations are always related to cases that accord-
ing to the clinician’s discretion require a personalized 
therapeutic approach (7,8). recent studies in patients 
with moderate disease showed that clobetasol pro-
pionate 0.05% ointment was as effective and safe as 
oral prednisone at 0.5 mg/kg/day (31). this particu-
lar dose of oral prednisone is under evaluation, as 
it seems to be safer but not less effective compared 
to higher doses. recent studies have shown that the 
monoclonal anti-CD20 antibody rituximab (375 mg/
m2/week for 4 weeks) and anti-ige antibody omali-
zumab (300 mg/4-8weeks) could be effective in pem-
phigus and bullous pemphigoid respectively, but fur-
ther evidence is needed (32,33). it is also noteworthy 
that administration of rituximab, an anti-CD20 mono-
clonal antibody which constitutes a high cost ther-
apy, is a common and simple practice in most cen-
tral european countries, unlike the rest of southern 
europe including Greece and Middle east countries, 
where the drug approval includes very time-consum-
ing paperwork.
the main consideration regarding AiBDs man-
agement remains their chronic and recurrent nature. 
relapses of intraepidermal AiBD seem to be more 
common and more difficult to manage than those of 
subepidermal AiBD. Finding new therapeutic targets 
that will relieve our patients from the short- and long-
term side-effects of systemic corticosteroids is an on-
going challenge.
CONCLUSION
this is a report from a tertiary AiBD referral Cen-
ter in northern Greece. Our data from a 4-year period 
contribute to the completion of a global geographic 
incidence map of AiBD.
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